PALO ALTO, Calif.–(BUSINESS WIRE)– Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced today that Blue Cross and Blue Shield of Louisiana now offers coverage for the Guardant Reveal™ molecular residual disease (MRD) test. Guardant Reveal is a blood test that detects circulating tumor DNA (ctDNA) in blood after treatment, including surgery, to help oncologists identify cancer patients with residual or recurring disease who may benefit most from adjuvant therapy or surveillance. It was the first blood-only liquid biopsy test commercially available for MRD testing.
Author: Abhay Panchal
Join us as we explore gastrointestinal (GI) knowledge with renowned expert Dr. Michael Byrne. With extensive medical and AI expertise, Michael provides a unique perspective on early cancer diagnosis and the challenges in detecting GI cancers. From colon to stomach and esophageal cancer, discover advancements in screening techniques and the role of AI in improving outcomes. Uncover the potential of AI solutions in revolutionizing GI healthcare and catching cancer early.
Some gastroenterology leaders say consolidation is the only way for many practices to survive as operating costs soar and margins tighten. U.S. Digestive Health CEO Jerry Tillinger joined Becker’s to discuss the upsides to consolidation. Editor’s note: This response was edited lightly for length and clarity. Question: How is GI industry consolidation affecting the delivery of patient care? Jerry Tillinger: As we come together as a large organization, we bring resources and capabilities to practices that didn’t have them before. Our ability to expand endoscopy centers and more rapidly to meet the market is easier for us to do in…
ATLANTA , July 19, 2023 /PRNewswire/ — United Digestive is pleased to announce that 18 physicians from two provider practices, Atlanta Gastroenterology Associates (AGA) and DeKalb Gastroenterology Associates (DGA), have been named “Top Doctors” in Atlanta Magazine’s 2023 annual guide of metro area providers. This recognition further solidifies the world-class GI care provided to our patients. Winners were nominated by their peers and selected after an extensive screening process was completed by Professional Research Services.
The widespread adoption of electronic health records (EHR) has raised concerns about increased workload and burnout among healthcare providers. However, the specific impact of EHR burden on gastroenterology (GI) providers still needs to be studied. For a study, researchers sought to examine the EHR use among outpatient GI providers and explore potential differences based on provider characteristics, including sex, subspecialty, and training status (physicians vs. nonphysician providers [NPPs]).
First Wave BioPharma’s bid to challenge AbbVie for a gastrointestinal market has suffered a setback, with the biotech telling investors “it is likely the primary efficacy endpoint was not achieved.” Florida-based First Wave is developing a formulation of adrulipase, a yeast-based alternative to AbbVie’s Creon and other pig-derived pancreatic enzyme replacement therapies. The therapies are used to treat nutritional deficiencies related to conditions including cystic fibrosis. First Wave bet its enzyme is a safer option with a lower pill burden and simplified sourcing that eliminates the risk of pathogen transmission.
CHICAGO—For managing colorectal lesions not sufficiently treated with a first attempt, endoscopic submucosal dissection achieved high rates of en bloc and R0 resection with low rates of local recurrence and perforation in a largely North American patient population. “Salvage ESD is highly effective for the treatment of previously attempted colorectal lesions (PACL),” said Suchapa Arayakarnkul, MD, a post-doctoral research fellow at the Johns Hopkins Hospital, in Baltimore. “When ESD is performed by experts, adverse events are uncommon and most can be managed endoscopically. The results of our study support the role of ESD for PACL in the Western setting.”
A patient with long-standing irritable bowel syndrome came to her gastroenterologist after a flare, indicating that she had stopped responding to her medication She didn’t know what to do with the stress anymore and wanted to try a more natural method. The physician looked at her blankly and said, “We don’t offer any of that here.” We can do better.Chronic gastrointestinal disorders can be multi-faceted, and patients may not always respond to conventional care. I think we can all agree that psychosocial factors have a profound impact on GI functioning and there is mounting evidence supporting the negative impact that…
In this podcast episode, Tamara Duker Freuman, MS, RD, CDN, discusses how the work of gastroenterologists and dieticians can inform each other, approaching GI conditions as new science emerges and more.
The artificial intelligence chatbot ChatGPT can potentially be used as source of information for patients, as well as an aid to clinicians managing gastroesophageal reflux disease (GERD), a study has found. The researchers say the tool’s conversational format could improve clinical efficiency and reduce the volume of patient messages and calls, potentially diminishing clinician burnout. However, inconsistencies and content errors observed require a certain level of clinical oversight, caution the researchers, led by Jacqueline Henson, MD, with the Division of Gastroenterology, Duke University School of Medicine, Durham, North Carolina.